Recently, Health Yuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as ‘Health Yuan’) announced the official appointment of Mr. Zhang Qinglei as Vice President of the company. This move is a strategic step in Health Yuan’s ongoing efforts to upgrade its corporate strategy and strengthen its executive team with specialized expertise. Mr. Zhang brings extensive experience in pharmaceutical industry management, having held senior leadership roles at several well-known pharmaceutical companies, with deep expertise in R&D, manufacturing, and market operations. At Health Yuan, he will primarily oversee strategic planning, business expansion, and internal operational synergy, supporting the company’s breakthroughs in key areas such as innovative drugs, advanced drug formulations, and international expansion. Health Yuan stated that Mr. Zhang’s addition will further enhance the company’s governance capabilities and overall competitiveness, delivering greater value to both shareholders and patients. As a leading integrated pharmaceutical enterprise in China, Health Yuan has consistently increased R&D investment in recent years, optimized its product portfolio, and actively expanded into global markets. This executive appointment underscores the company’s strong confidence and clear roadmap for high-quality future growth.
近日，健康元药业集团股份有限公司（简称“健康元”）宣布正式聘任张庆雷先生为公司副总裁。此次任命是健康元在持续推进企业战略升级、强化管理团队专业化背景下的重要举措。张庆雷先生拥有多年医药行业管理经验，曾在多家知名医药企业担任高管职务，在研发、生产及市场运营等方面具备深厚积累。加入健康元后，他将主要负责公司战略规划、业务拓展及内部协同优化等工作，助力公司在创新药、高端制剂及国际化布局等关键领域实现突破。健康元表示，张庆雷的加入将进一步提升公司治理水平和综合竞争力，为股东和患者创造更大价值。作为国内领先的综合性医药企业，健康元近年来持续加大研发投入，推动产品结构优化，并积极拓展全球市场。此次高管团队的扩充，也彰显了公司对未来高质量发展的坚定信心与清晰路径。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/15736.html